




EUROPEAN PATENT APPLICATION

 Application number: 85111243.3


 Int. Cl.⁴: **C 07 D 215/60, C 07 D 405/12,**
A 61 K 31/47

 Date of filing: 05.09.85


 Priority: 07.09.84 JP 187752/84

 Applicant: **KYOWA HAKKO KOGYO CO., LTD., 6-1,**
Ohte-Machi Itchome, Chiyoda-ku Tokyo (JP)

 Date of publication of application: 16.04.86
 Bulletin 86/16


 Inventor: **Teranishi, Masayuki, 2-13-24, Narusedai,**
Machida-shi Tokyo (JP)
 Inventor: **Suzuki, Koji, 19-201, 2-14-4, Naruse,**
Machida-shi Tokyo (JP)
 Inventor: **Kase, Hiroshi, 3-35-18, Maehara-cho,**
Koganei-shi Tokyo (JP)
 Inventor: **Kitamura, Shigeto, 1-3-7, Naruse, Machida-shi**
Tokyo (JP)
 Inventor: **Shuto, Katsulchi, 410-1, Nameri,**
Nagazumi-cho, Sunto-gun Shizuoka-ken (JP)
 Inventor: **Omori, Kenji, 2-14-3, Fuyodai, Mishima-shi**
Shizuoka-ken (JP)

 Designated Contracting States: **DE FR GB IT**

 Representative: **Wilhelms, Rolf E., Dr. et al, WILHELMS,**
KILIAN & PARTNER Patentanwälte
Eduard-Schmid-Strasse 2, D-8000 München 90 (DE)

 **Quinoline-n-oxide derivative and pharmaceutical composition.**

 A quinoline-N-oxide derivative represented by the formula:



[wherein X is hydroxy, lower alkoxy, lower alkylthio, unsubstituted or substituted aralkyloxy, or unsubstituted or substituted aralkylthio; Y is a hydrogen atom or halogen atom; R₁ is alkylene or alkenylene having 3 to 15 carbon atoms; Z is hydroxymethyl, lower alkoxyethyl, unsubstituted or substituted aryloxyethyl, tetrahydropyranyloxyethyl, tetrahydrofuranyloxyethyl, unsubstituted or substituted arylsulfonyloxyethyl, lower alkylthiomethyl, unsubstituted or substituted arylthiomethyl, lower alkylsulfinylmethyl, unsubstituted or substituted arylsulfinylmethyl, lower alkylsulfonylmethyl, unsubstituted or substituted arylsulfonylmethyl, aminomethyl, -CH₂NHR₂ (wherein R₂ is lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl), -CH₂NR₃R₄ (wherein R₃ and R₄ are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or sub-

stituted aryl), -CH₂N⁺R₅R₆R₇ (wherein R₅, R₆, and R₇ are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl, where the counterion is an anion of acid or a hydroxyl ion), -COR₈ (wherein R₈ is a hydrogen atom, lower alkyl or hydroxy), -CH(OR₉)₂ (wherein R₉ is lower alkyl), iminomethyl, hydroxyiminomethyl, or a halogen atom] and its salts, can very strongly inhibit the lipoxigenase and considerably suppress production and release of its metabolites, and thus are useful as preventive and healing agents for the diseases caused by the lipoxigenase metabolites.

YOWA HAKKO KOGYO CO., LTD.

Tokyo / JAPAN

DR. RER. NAT. ROLF E. WILHELMS
DR. RER. NAT. HELMUT KILIAN
DR.-ING. JÜRGEN SCHMIDT-BOGATZKY *

QUINOLINE-N-OXIDE DERIVATIVE AND
PHARMACEUTICAL COMPOSITION

EDUARD-SCHMID-STRASSE 2
8000 MÜNCHEN 90

Priority: Sept. 7, 1984-Japan-No. 187752/84

TELEFON (089) 652091
TELEX 523467 (wilp-d)
TELEGRAMME PATRANS MÜNCHEN
TELEFAX G3/G2 (089) 6516206
P 2644-EP

Background of the Invention

The present invention relates to a quinoline-N-oxide derivative having a lipoxxygenase-inhibiting action and a pharmaceutical composition containing the same.

Lipoxxygenase (1. 13. 11. 12) is an enzyme existing in blood platelets, leukocytes, lymphocytes, etc., and converts polyvalent unsaturated fatty acid (particularly arachidonic acid) to hydroperoxy acid. It is known that positions of hydroperoxy group(s) introduced in arachidonic acid by lipoxxygenase are 5th, 8th, 9th, 11th, 12th and 15th positions. For example, it has been reported that lipoxxygenase existing mostly in blood platelets, etc. is an enzyme that hydroperoxidizes the 12th position of arachidonic acid (12-lipoxxygenase), and there are 5-lipoxxygenase and 15-lipoxxygenase in leukocytes. Hydroperoxyeicosatetraenoic acid formed from arachidonic acid by lipoxxygenase is unstable and is converted to hydroxyeicosatetraenoic acid. These fatty acids formed by lipoxxygenase stimulate by themselves physiological actions such as migration of leukocytes and smooth muscles of aortic tunica media, etc., and it has been recently clarified that they are further metabolized in vivo to produce metabolic products having various physiological actions. For example, chemical structure and biosynthesis route of a slow reacting substance of anaphylaxis (abbreviated as SRS-A, which includes leukotriene C, D, E and F) which is formed in lungs of guinea pigs at anaphylaxis or human lungs at asthmatic attacks and has a force to slowly but strongly contract the smooth muscles of bronchus and which has long been regarded as a substance to cause asthma have been recently clarified by Samuelson et al.


[Proc. Natl. Acad. Sci. U.S., 77, 2014 (1980)], and it has been found that it is formed by metabolism from arachidonic acid by aid of 5-lipoxygenase. It has been reported that various peroxy lipids such as hydroperoxyeicosatetraenoic acid, hydroxyeicosatetraenoic acid, leucotriene B, SRS-A, etc. which are formed by metabolism by aid of lipoxygenase, are chemical mediators that contract various smooth muscles, for example, smooth muscles of respiratory system (trachea, bronchus, pulmonary tissue), vascular system, digestive organ; accelerate capillary permeability, stimulate migration of leukocytes and smooth muscles of aortic tunica media, and as the result cause bronchial asthma, allergic diseases (atopic dermatitis, inflammation of organs, etc.), diseases of circulatory organs (edema, ischemic heart disease, hypertension, ischemic brain disturbance, arteriosclerosis, etc.) or cause inflammatory diseases.

However, studies of effective compounds on the diseases caused by the lipoxygenase metabolites have not been advanced yet.

As a result of searching preventive and healing agents for the diseases caused by the lipoxygenase metabolites, it has been found that quinoline-N-oxide derivatives are useful as preventive and healing agents, for the diseases caused by the lipoxygenase metabolites.

Summary of the Invention

The present invention relates to a quinoline-N-oxide derivative represented by the formula (I):




(I)

[wherein X is hydroxy, lower alkoxy, lower alkylthio, unsubstituted or substituted aralkyloxy, or unsubstituted

or substituted aralkylthio; Y is a hydrogen atom or halogen atom; R_1 is alkylene or alkenylene having 3 to 15 carbon atoms; Z is hydroxymethyl, lower alkoxymethyl, unsubstituted or substituted aryloxymethyl, tetrahydro-
 5 pyraniloxyethyl, tetrahydrofuraniloxyethyl, unsubstituted or substituted arylsulfonyloxyethyl, lower alkylthio-
 methyl, unsubstituted or substituted arylthiomethyl, lower alkylsulfinylmethyl, unsubstituted or substituted aryl-
 sulfinylmethyl, lower alkylsulfonylmethyl, unsubstituted
 10 or substituted arylsulfonylmethyl, aminomethyl, $-CH_2NHR_2$ (wherein R_2 is lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl), $-CH_2NR_3R_4$ (wherein R_3 and R_4 are lower alkyl, unsubstituted or sub-
 stituted aralkyl, or unsubstituted or substituted aryl),
 15 $-CH_2N^+R_5R_6R_7$ (wherein R_5 , R_6 and R_7 are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl, where the counterion is an anion of acid or a hydroxyl ion), $-COR_8$ (wherein R_8 is a hydrogen atom, lower alkyl or hydroxy), $-CH(OR_9)_2$ (wherein R_9 is
 20 lower alkyl), iminomethyl, hydroxyiminomethyl or a halogen atom] [hereinafter referred to as "compound (I)", and compounds of other formula numbers will be hereinafter likewise referred to] and its salts, and a pharmaceutical composition containing a compound (I) or a pharmacolo-
 25 gically acceptable salt thereof. Compounds (I) and their salts can very strongly inhibit the lipooxygenase and considerably suppress production and release of its meta-
 bolites, and thus are useful as preventive and healing agents for the diseases caused by the lipooxygenase meta-
 30 bolites.

Detailed Description of the Invention

The compound (I) where $X=OH$ can exist as a tautomer as shown by the following equation, and thus it
 35 is needless to say that the present invention includes these tautomers:



10

In the definitions of the respective groups in the formula (I), the lower alkyl appearing in the lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, and lower alkyl includes linear or branched
15 alkyls having 1 to 4 carbon atoms, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, etc.

In the definitions of the respective groups, the aralkyl appearing in the aralkyloxy, aralkylthio, and aralkyl includes those whose aryl moiety is phenyl or
20 naphthyl and whose alkyl moiety is alkyl having 1 to 3 carbon atoms, for example, methyl, ethyl, etc.

In the definitions of the respective groups, the aryl appearing in the aryloxy, arylthio, arylsulfonyl, and aryl is phenyl or naphthyl. The substituent appearing in
25 the substituted aralkyloxy, substituted aralkylthio, substituted aralkyl, substituted aryloxymethyl, substituted arylsulfonyloxymethyl, substituted arylthiomethyl, substituted arylsulfinylmethyl, substituted arylsulfonylmethyl, and substituted aryl is a substituent on the aryl
30 ring and includes lower alkyl, lower alkoxy, halogen atoms (chlorine, bromine, etc.), nitro, hydroxyl, etc., where the lower alkyl and lower alkoxy have the same meanings as defined above.

In the definitions of the respective groups in the formula (I), the halogen atom includes chlorine,
35 bromine, iodine, etc. The alkylene and alkenylene having 3 to 15 carbon atoms as R_1 are linear or branched, and



include, for example, trimethylene, pentamethylene, heptamethylene, octamethylene, nonamethylene, decamethylene, undecamethylene, dodecamethylene, tridecamethylene, tetradecamethylene, pentadecamethylene, propenylene, etc.


5 From the viewpoint of pharmacological effect, alkylene and alkenylene having 5 to 15 carbon atoms are preferable.

When the compound (I) is an acidic compound, a base addition salt can be prepared, whereas when it is a basic compound, an acid addition salt can be prepared.


10 The salt of the acidic compound is preferably a pharmacologically acceptable salt, and includes alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, and salts of organic bases such as ethanolamine, triethylamine, morpholine, piperidine, piperazine, etc. The acid
15 salt of the basic compound includes inorganic and organic acid salts, and such an acid salt is preferably a pharmacologically acceptable salt and includes, for example, hydrochloride, sulfate, nitrate, acetate, oxalate,
20 fumarate, citrate, etc.

The compound (I) can be prepared according to the following reaction procedures:







5




10




15








20



30



35



(wherein X_1 is X excluding hydroxy, that is, lower alkoxy, lower alkylthio, unsubstituted or substituted aralkyloxy, or unsubstituted or substituted aralkylthio; Y_1 is Y excluding hydrogen, that is, a halogen atom; R_1 has the same meaning as defined above; Hal is a halogen atom, for example, chlorine, bromine, and iodine).

First of all, compound (III) is prepared by reaction of compound (II) with a Grignard's reagent [prepared from $t\text{Bu}(\text{Me})_2\text{SiOCH}_2\text{R}_1\text{Hal}$ and magnesium].

The reaction can be carried out in an ethereal solvent such as tetrahydrofuran, dioxane, etc. under mild conditions nearly at room temperature or below. It is preferable to use at least about one mole, preferably about 1.5 to about 2 moles of the Grignard's reagent per mole of the compound (II). After the reaction, the remaining excess Grignard's reagent is decomposed, for example, by adding water thereto, and then the solvent is removed therefrom by distillation. The residues thus obtained are dissolved in an appropriate inert solvent, for example, a halogenated hydrocarbon such as methylene chloride, chloroform, carbon tetrachloride, etc., and the solution is treated with an organic peroxide, for example, perbenzoic acid, m-chloroperbenzoic acid, peracetic acid, etc. in a substantially equimolar amount or a little excess amount, in respect to the compound (II), with ice cooling, whereby the compound (III) can be obtained.

The compound (III) thus obtained is subjected to hydrolysis reaction with hydrochloric acid, etc. in a solvent, for example, alcohol such as methanol, ethanol, propanol, etc., acetone, etc. at room temperature, whereby compound (I-1) can be obtained.

Then, the compound (I-1) is halogenated, if necessary, whereby compound (I-2) can be obtained. The halogenation can be carried out according to the ordinary procedure using the ordinary halogenating agent, such as N-chlorosuccinimide, N-bromosuccinimide, etc. For example, when the halogenation is carried out with N-halosuccinimide,

the compound (I-1) is dissolved in an appropriate solvent, for example, an alcohol such as methanol, ethanol, etc., or a halogenated hydrocarbon such as dichloromethane, chloroform, etc., and a substantially equimolar amount of
 5 N-halosuccinimide is added thereto. Then, the mixture is stirred at room temperature, whereby the compound (I-1) can be converted to the compound (I-2).

On the other hand, the compound (I-1) is dissolved in an appropriate inert solvent, for example, a
 10 halogenated hydrocarbon such as methylene chloride, chloroform, carbon tetrachloride, etc., and treated with dihydropyran in a substantially equimolar amount or a little excess amount in respect to the compound (I-1) and a catalytic amount of p-toluenesulfonic acid or a catalytic
 15 amount of D-camphorsulfonic acid or the like at room temperature, whereby the compound (I-1) can be converted to compound (I-3). A compound (I-3) wherein X_1 is a benzyloxy group can be converted to compound (I-4) by a well-known hydrogenolysis reaction. For example, the
 20 compound (I-4) can be obtained by reducing the compound (I-3) with hydrogen under the atmospheric pressure or under a superatmospheric pressure at room temperature in a solvent such as methanol, ethanol, etc. in the presence of a hydrogenating catalyst such as palladium-carbon,
 25 platinum black, Raney nickel, etc. On the other hand, compound (I-5) can be obtained by hydrogenolyzing a compound (I-1) where X_1 is a benzyloxy group in the same manner as described above. Compound (I-6) can be obtained, if necessary, by halogenating the compound (I-5) in the
 30 same manner as described above. The compound (I-1) can be converted to compound (I-7) by dissolving the compound (I-1) in an appropriate inert solvent, for example, a halogenated hydrocarbon such as methylene chloride, chloroform, carbon tetrachloride, etc. and oxidizing the compound
 35 (I-1) with pyridinium chlorochromate in a substantially equimolar amount or an excess amount in respect to the compound (I-1) at room temperature.

Furthermore, the compound (I-7) can be converted to compound (I-8) by dissolving the compound (I-7) in a solvent such as acetone, etc., and treating the compound (I-7) with an excess amount of Jones' reagent with ice cooling. A compound (I-8) where X_1 is a benzyloxy group can be converted to compound (I-9) by hydrogenolysis in the same manner as above, and furthermore the compound (I-9) can be converted to compound (I-10), if necessary, by halogenation in the same manner as above.

On the other hand, the compound (I-7) can be converted to compound (I-11) by treating the compound (I-7) with ammonium acetate and sodium cyanoborohydride in a solvent such as methanol, ethanol, etc. with ice cooling. A compound (I-11) where X_1 is a benzyloxy group can be converted to compound (I-12) by hydrogenolysis in the same manner as above, and furthermore the compound (I-12) can be converted to compound (I-13), if necessary, by halogenation in the same manner as above.

The compound (I-7) can be converted to compound (I-14) by treatment with benzylamine in a solvent such as methanol, ethanol, etc. at room temperature and then by reduction with sodium borohydride with ice cooling. A compound (I-14) where X_1 is a benzyloxy group can be converted to compound (I-15) by hydrogenolysis in the same manner as above, and furthermore the compound (I-15) can be converted to compound (I-16), if necessary, by halogenation in the same manner as above.

Furthermore, the compound (I-7) can be converted to compound (I-17) by treatment with hydroxylamine hydrochloride at room temperature in a solvent such as methanol, ethanol, etc. A compound (I-17) where X_1 is a benzyloxy group can be converted to compound (I-18) by hydrogenolysis in the same manner as above, and furthermore the compound (I-18) can be converted to compound (I-19), if necessary, by halogenation in the same manner as above.

Furthermore, the compound (I-7) can be converted to compound (I-20) by adding compound (I-7) and 2,2-

dimethoxypropane to an appropriate inert solvent such as methylene chloride, chloroform, carbon tetrachloride, etc. and stirring the mixture in the presence of an acid catalyst such as p-toluenesulfonic acid, D-camphorsulfonic acid, etc. at room temperature. A compound (I-20) where X_1 is a benzyloxy group can be converted to compound (I-21) by hydrogenolysis in the same manner as above, and the compound (I-21) can be converted to compound (I-22) by halogenation in the same manner as above.

10 Furthermore, a compound (I-7) where X_1 is a benzyloxy group can be converted to compound (I-23) by hydrogenolysis in the same manner as above, and the compound (I-23) can be converted to compound (I-24), if necessary, by halogenation in the same manner as above.

15 The compound (I) thus prepared, i.e. compounds (I-1) to (I-24) can be purified by a well-known purification procedure, for example, by recrystallization, column chromatography using silica gel, etc., extraction, etc.

20 The present invention also relates to a preventive and healing composition for diseases due to lipoxigenase metabolic products, which comprises an effective amount of a compound (I) or a pharmacologically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. The compound (I) and its salts strongly inhibit
25 the lipoxigenase activity. The compound (I) and its pharmacologically acceptable salts are useful for healing and preventing, or treating bronchial asthma, various allergic diseases (allergic rhinitis, urticaria, etc.), ischemic heart disease, hypertension, ischemic brain disturbance,
30 arteriosclerosis, inflammatory diseases, etc., caused by lipoxigenase metabolites. Dosage for these purposes depends upon the desired healing effect, way of administration, healing period, age, body weight, etc., and usually is 0.5 - 20 mg/kg per day for an adult human as compounds
35 (I) through oral or parenteral route (for example, injection, application, inhalation, etc.). Compound (I) or a salt thereof can be administered as such, but generally

administered in the form of tablets, pills, powder,
granules, capsules, suppository, injection, etc. Carriers
used for the pharmaceutical composition include lactose,
dextrose, sucrose, sorbitol, mannitol, glucose, cellulose,
5 cyclodextrin, talc, starch, methylcellulose, gelatin,
arabic gum, polyethylene glycol, carboxymethylcellulose,
hydroxypropylcellulose, sodium benzoate, sodium hydrogen
sulfite, aluminium stearate, magnesium stearate, mineral
oil, vegetable oil, white vaseline, liquid paraffin, etc.,
10 and can be appropriately selected in view of the kind of
preparations. The present composition can contain 0.01 -
85 weight percent of compound (I).

Examples and Experimental Example of the present
invention are given below:

15 Example 1

1-(1) Preparation of 4-benzyloxy-2-(11-t-butyl-
dimethylsilyloxyundecyl) quinoline-N-oxide

20 The Grignard's reagent prepared from 7.5 m moles
of 11-t-butyltrimethylsilyloxyundecyl bromide and 7.5 m moles
of magnesium is dropwise added to a tetrahydrofuran solu-
tion containing 5 m moles of 4-benzyloxyquinoline-N-oxide
with ice cooling and the mixture is stirred at the same
25 temperature for one hour. Then, water is added by portions
thereto to decompose the reagent, and then the mixture is
extracted with chloroform. The solvent is removed from
the extract by distillation, and the residue is dissolved
in methylene chloride, and an aqueous saturated solution
30 of sodium hydrogen carbonate is added to the solution, and
further 5 m moles of ice-cooled metachloroperbenzoic acid
is added thereto. Then, the mixture is stirred for 30
minutes. Then, the reaction solution is washed with an
aqueous saturated solution of sodium hydrogen carbonate
35 and then with water, and dried over anhydrous sodium
sulfate. Then, the solvent is removed therefrom by dis-
tillation. The residue is purified by silica gel column

procedure, whereby the captioned compound can be obtained as a colorless oily substance (yield: 88.0%).

NMR (CDCl₃) δ (ppm): 0.35(6H, s, Me x 2), 0.86(9H, s, Me x 3), 3.14(2H, t, J=6Hz, ArCH₂), 3.61(2H, t, J=6Hz, -OCH₂), 5.30(2H, s, OCH₂Ar), 6.70(1H, s, ArH), 8.28(1H, dd, J=1.5Hz, 8Hz, ArH), 8.87(1H, dd, J=1.5Hz, 8Hz, ArH)

1-(2) Preparation of 4-benzyloxy-2-(11-hydroxyundecyl) quinoline-N-oxide

At first, 5 m moles of 4-benzyloxy-2-(11-t-butyl-dimethylsilyloxyundecyl) quinoline-N-oxide is dissolved in methanol, and an aqueous 10% hydrochloric acid solution is added thereto. Then, the mixture is stirred at room temperature for 3 hours. After removal of the solvent therefrom by distillation, the residue is extracted with chloroform, and the extract is washed with an aqueous saturated sodium hydrogen carbonate solution, and then with water, and dried over anhydrous sodium sulfate, and the solvent is removed therefrom by distillation. The residue is purified by silica gel column procedure, whereby the captioned compound is obtained as colorless crystals (yield: 88.4%).

NMR (CDCl₃) δ (ppm): 3.12(2H, t, J=7.5Hz, ArCH₂), 3.60(2H, t, J=6Hz, CH₂OH), 5.30(2H, s, OCH₂Ar), 6.69(1H, s, ArH), 8.25(1H, dd, J=1.5Hz, 8Hz, ArH), 8.79(1H, dd, J=1.5Hz, 8.5Hz, ArH)

Example 2

In the same manner as in Example 1, 4-benzyloxy-2-(3-hydroxypropyl) quinoline-N-oxide is obtained.

NMR (CDCl₃ + CD₃OD) δ (ppm): 2.40(2H, q, J=5Hz, CH₂-CH₂CH₂), 3.29(2H, t, J=5Hz, Ar-CH₂-), 3.68(2H, t, J=5Hz, CH₂OH), 5.40(2H, s, -OCH₂Ar), 6.98(1H, s, ArH), 8.38(1H, dd, J=1.5Hz, 8Hz, ArH), 8.74(1H, dd, J=1.5Hz, 8Hz, ArH).

Example 3

Preparation of 4-hydroxy-2-(11-hydroxyundecyl) quinoline-N-oxide

In this example, 4-benzyloxy-2-(11-hydroxy-undecyl) quinoline-N-oxide is dissolved in methanol and catalytically reduced with a catalyst of 10% palladium-carbon under the atmospheric pressure. Then, the catalyst is removed therefrom by filtration, and the solvent is also removed therefrom by distillation. The residue is recrystallized from ethanol, whereby the cationed compound is obtained (yield: 57.5%).

NMR (CDCl₃ + CD₃ OD) δ (ppm): 2.91(2H, t, J=6Hz, CH₂Ar), 3.57(2H, t, J=6Hz, CH₂OH), 6.35(1H, s, ArH), 8.16(1H, dd, J=1.5Hz, 8Hz, ArH), 8.30(1H, dd, J=1.5Hz, 8Hz, ArH)

Example 4

In the same manner as in Example 3, 4-hydroxy-2-[3-(2-tetrahydropyranyloxy) propyl] quinoline-N-oxide is obtained.

NMR (CDCl₃ + CD₃ OD) δ (ppm): 2.34(2H, q, J=6Hz, -CH₂CH₂CH₂-), 2.90(2H, t, J=6Hz, ArCH₂-), 4.54(1H, br.s, -O-CH-O-), 6.21(1H, s, ArH), 8.14(1H, dd, J=1.5Hz, 8Hz, ArH), 8.29(1H, dd, J=1.5Hz, 8Hz, ArH).

Example 5

Preparation of 3-bromo-4-hydroxy-2-(11-hydroxyundecyl) quinoline-N-oxide

In this example, 1 m mole of 4-hydroxy-2-(11-hydroxyundecyl) quinoline-N-oxide is dissolved in a liquid mixture of methanol - chloroform (5:1), and 1 m mole of N-bromosuccinimide is added thereto. The mixture is stirred at room temperature for one hour. After the reaction, the solvent is removed therefrom by distillation, and the residue is recrystallized from ethanol, whereby the captioned compound is obtained (yield: 70.5%).

NMR ($\text{CDCl}_3 + \text{CD}_3\text{OD}$) δ (ppm): 3.25 (2H, t, $J=6.5\text{Hz}$, ArCH_2-), 3.91 (2H, t, $J=6\text{Hz}$, CH_2OH), 7.96 (1H, dd, $J=1.5\text{Hz}$, 8Hz, ArH), 8.36 (1H, dd, $J=1.5\text{Hz}$, 8Hz, ArH).

5

Example 6

Preparation of 4-benzyloxy-2-[11-(2-tetrahydro-
pyranyloxy) undecyl] quinoline-N-oxide

In this example, 5 m moles of 4-benzyloxy-2-(11-
10 hydroxyundecyl)-quinoline-N-oxide is dissolved in dichloro-
methane, and a catalytic amount of D-camphorsulfonic acid
and 6 m moles of 2,3-dihydropyran are added thereto. The
mixture is stirred at room temperature for 3 hours. Then,
the reaction solution is washed with an aqueous sodium
15 hydrogen carbonate solution and then with water, and dried
over anhydrous sodium sulfate. The solvent is removed
therefrom by distillation, and the residue is purified by
silica gel column procedure, whereby the cationed compound
is obtained as a colorless oily substance (yield: 82.3%).

20 NMR (CDCl_3) δ (ppm): 3.13 (2H, t, $J=6.5\text{Hz}$, CH_2Ar),
4.55 (1H, t, $J=2\text{Hz}$, $-\text{OCHO}-$), 5.27 (2H, s, OCH_2Ar),
6.68 (1H, s, ArH), 8.27 (1H, dd, $J=1.5\text{Hz}$, 8Hz,
 ArH), 8.83 (1H, dd, $J=1.5\text{Hz}$, 8Hz, ArH).

25 Example 7

Preparation of 4-benzyloxy-2-(10-formyldecyl)
quinoline-N-oxide

In this example, 5 m moles of 4-benzyloxy-2-(11-
hydroxyundecyl) quinoline-N-oxide is dissolved in dichloro-
30 methane, and 15 m moles of pyridinium chlorochromate is
added thereto. Then, the mixture is stirred at room tem-
perature for 2.5 hours. The reaction solution is washed
with water and dried over anhydrous sodium sulfate, and
the solvent is removed therefrom by distillation. The
35 residue is purified by silica gel column procedure, whereby
the captioned compound is obtained as a colorless oily
substance (yield: 79.2%).

NMR (CDCl₃) δ (ppm): 2.40(2H, t, J=6Hz, CH₂Ar),
 3.16(2H, t, J=8Hz, CH₂CHO), 5.31(2H, s, OCH₂Ar),
 6.70(1H, s, ArH), 8.26(1H, dd, J=1.5Hz, 8Hz,
 ArH), 8.84(1H, dd, J=1.5Hz, 8Hz, ArH), 9.77(1H,
 6, J=2Hz, CHO).

Example 8

Preparation of 4-benzyloxy-2-(10-carboxydecyl)
 quinoline-N-oxide

In this example, 5 m moles of 4-benzyloxy-2-(10-
 formyldecyl) quinoline-N-oxide is dissolved in acetone,
 and 10 m moles of Jones' reagent prepared from chromium
 trioxide, sulfuric acid and water is added thereto with
 ice cooling. The mixture is stirred for 5 minutes. After
 the reaction, water is added thereto, and the reaction
 mixture is extracted with chloroform. The extract is
 dried over anhydrous sodium sulfate, and then the solvent
 is removed therefrom by distillation. The residue is
 purified by silica gel column procedure, whereby the
 captioned compound is obtained as colorless crystals
 (yield: 31.0%).

NMR (CDCl₃) δ (ppm): 2.32(2H, t, J=6.5Hz, CH₂Ar),
 3.22(2H, t, J=8.0Hz, CH₂CO₂H), 5.33(2H, s,
 OCH₂Ar), 6.76(1H, s, ArH), 8.32(1H, dd, J=1Hz,
 8Hz, ArH), 8.83(1H, dd, J=1Hz, 8Hz, ArH).

Example 9

Preparation of 4-benzyloxy-2-(11-aminoundecyl)
 quinoline-N-oxide

In this example, 5 m moles of 4-benzyloxy-2-
 (10-formyldecyl) quinoline-N-oxide is dissolved in methanol,
 and 50 m moles of ammonium acetate and 15 m moles of sodium
 cyanoborohydride are added thereto with ice cooling. Then,
 the mixture is stirred for 1.5 hours. After the reaction,
 the solvent is removed therefrom by distillation, and then
 the mixture is extracted with chloroform. The chloroform
 layer is dried over anhydrous sodium sulfate, and the

5 NMR (CDCl₃) δ (ppm): 2.60 (2H, br.s, CH₂NH₂), 3.16 (2H, t, J=8Hz, CH₂Ar), 5.30 (2H, s, OCH₂Ar), 6.71 (1H, s, ArH), 8.30 (1H, dd, J=1Hz, 8Hz, ArH), 8.85 (1H, dd, J=1Hz, 8Hz, ArH)

Preparation of 4-benzyloxy-2-[11-(N-benzylamino-undecyl)] quinoline-N-oxide

NMR (CDCl₃) δ (ppm): 2.62 (2H, t, J=6.5Hz, NHCH₂)
3.15 (2H, t, J=8Hz, CH₂Ar), 3.89 (2H, s, NHCH₂Ar),
5.30 (2H, s, OCH₂Ar), 6.68 (1H, s, ArH), 8.26
(1H, dd, J=1Hz, 8Hz, ArH), 8.86 (1H, dd, J=1Hz,
8Hz, ArH).

Example 11

Preparation of 4-benzyloxy-2-[10-(N-hydroxy-
iminodecyl)] quinoline-N-oxide

In this example, 5 m moles of 4-benzyloxy-2-(10-
5 formyldecyl) quinoline-N-oxide is dissolved in methanol
and 5 m moles of hydroxylamine hydrochloride is added
thereto. The mixture is stirred at room temperature for
3 hours. The solvent is removed therefrom by distillation,
and an aqueous saturated sodium hydrogen carbonate solu-
10 tion is added to the residue. Then, the mixture is
extracted with chloroform, and the organic layer is dried
over anhydrous sodium sulfate. Then, the solvent is
removed therefrom by distillation, and the residue is
purified by silica gel column procedure, whereby the
15 captioned compound is obtained as a colorless oily sub-
stance (yield: 72.0%).

NMR (CDCl₃) δ (ppm): 2.15(1H, q, J=6Hz, HCH-CH=N-),
2.30(1H, q, J=6Hz, HCH-CH=N-), 3.17(2H, t, J=
8Hz, CH₂Ar), 5.31(2H, s, OCH₂Ar), 6.71(1H, s,
20 ArH), 8.28(1H, dd, J=1Hz, 8Hz, ArH), 8.89(1H,
dd, J=1Hz, 8Hz, ArH).

Example 12

Preparation of 4-benzyloxy-2-(11,11-dimethoxy-
25 undecyl) quinoline-N-oxide

In this example, 5 m moles of 4-benzyloxy-2-(10-
formyldecyl) quinoline-N-oxide is dissolved in dichloro-
methane, and a catalytic amount of D-camphorsulfonic acid
and a large excess of 2,2-dimethoxypropane are added
30 thereto. The mixture is stirred at room temperature for
3 hours. After the reaction, the reaction solution is
washed with an aqueous saturated sodium hydrogen carbonate
solution, and then with water, and dried over anhydrous
sodium sulfate. After removal of the solvent by distilla-
35 tion, the residue is purified by silica gel column proce-
dure, whereby the captioned compound is obtained as a
colorless oily substance (yield: 70.6%).

NMR (CDCl₃) δ (ppm): 3.16 (2H, t, J=7Hz, CH₂Ar),
 3.36 (6H, s, OMe x 2), 4.38 (1H, t, J=5Hz, CH(OMe)₂),
 5.32 (2H, s, OCH₂Ar), 6.71 (1H, s, ArH), 8.30 (1H,
 dd, J=1Hz, 8Hz, ArH), 8.87 (1H, dd, J=1Hz, 8Hz,
 ArH).

Examples 13 - 20

In the same manner as in Examples 1 and 3, compounds shown in the following Table 1 are obtained.

Table 1

Ex. No.	Compound	NMR δ (ppm)
13	4-benzyloxy-2-[3-(2-tetrahydropyranyloxy) propyl] quinoline-N-oxide	CDCl ₃ , 2.12 (2H, t, J=7.5Hz, CH ₂ CH ₂ CH ₂), 3.23 (2H, t, J=8Hz, CH ₂ Ar), 4.54 (1H, br.s, -OCHO-), 5.26 (2H, s, OCH ₂ Ar), 6.76 (1H, s, ArH), 8.22 (1H, dd, J=1.5Hz, 8Hz, ArH), 8.76 (1H, d, J=8Hz, ArH)
14	4-hydroxy-2-[11-(2-tetrahydropyranyloxy) undecyl] quinoline-N-oxide	CDCl ₃ , 2.43 (2H, t, J=7Hz, CH ₂ Ar), 4.58 (1H, br.s, -OCHO-), 5.99 (1H, s, ArH), 7.17-8.32 (4H, m, ArH)
15	4-hydroxy-2-(10-carboxydecyl) quinoline-N-oxide	CDCl ₃ + CD ₃ OD, 2.30 (2H, t, J=7.5Hz, CH ₂ CO ₂ H), 2.95 (2H, t, J=8Hz, CH ₂ Ar), 6.36 (1H, s, ArH), 7.4-8.40 (4H, m, ArH)
16	4-hydroxy-2-(11-aminoundecyl) quinoline-N-oxide hydrochloride	CDCl ₃ + CD ₃ OD, 2.99 (2H, t, J=7.5Hz, CH ₂ NH ₂), 3.25 (2H, t, J=8Hz, CH ₂ Ar), 7.16 (1H, s, ArH), 7.77-8.60 (4H, m, ArH)

Ex. No.	Compound	NMR δ (ppm)
5	17 4-hydroxy-2-[11-(N-benzylaminoundecyl)] quinoline-N-oxide	CDCl ₃ , 2.50 (2H, br.s, $\text{CH}_2\text{NHCH}_2\text{-Ar}$), 2.72 (2H, dist. t, $J=7.5\text{Hz}$, ArCH_2), 3.93 (2H, s, CH_2NHAr), 5.88 (1H, s, ArH), 7.99 (1H, d, $J=8\text{Hz}$, ArH), 8.17 (1H, d, $J=8\text{Hz}$, ArH)
10	18 4-hydroxy-2-[10-(N-hydroxyiminodecyl)] quinoline-N-oxide	CDCl ₃ , 2.16 (2H, q, $J=5\text{Hz}$, $\text{CH}_2\text{CH=N-}$), 2.99 (2H, t, $J=6\text{Hz}$, CH_2Ar), 6.46 (1H, s, ArH), 6.68 (1H, t, $J=5\text{Hz}$, CH=N-), 7.35-8.40 (4H, m, ArH)
15	19 4-hydroxy-2-(11,11-dimethoxyundecyl) quinoline-N-oxide	CDCl ₃ , 2.48 (2H, t, $J=8\text{Hz}$, CH_2Ar), 3.36 (6H, s, $\text{OMe} \times 2$), 4.42 (1H, t, $J=6\text{Hz}$, CH(OMe)_2), 6.04 (1H, s, ArH), 7.30-8.35 (4H, m, ArH)
20	20 4-hydroxy-2-(10-formyldecyl) quinoline-N-oxide	CDCl ₃ , 2.40 (2H, t, $J=8\text{Hz}$, ArCH_2), 2.81 (2H, br.s, CH_2CHO), 6.40 (1H, s, ArH), 8.10 (1H, d, $J=8\text{Hz}$, ArH), 8.30 (1H, d, $J=8\text{Hz}$, ArH), 9.77 (1H, t, $J=2\text{Hz}$, CHO)
25		

30

Example 21 Tablets

35 A 10% hydroxypropylcellulose solution is added to a mixture consisting of 100 g of 4-benzoyloxy-2-(11-hydroxyundecyl) quinoline-N-oxide, 40 g of lactose, 18 g of corn starch and 10 g of carboxymethylcellulose calcium, and the mixture is kneaded. The mixture is then granulated

by an extrusion granulator with 1.0 mm basket, and the granules are dried at 60°C. The dried granules are screened on a 16-mesh sieve, and magnesium stearate is added to the screened granules to prepare tabletting
5 granules. According to the ordinary procedure, tablets, 8 mm in size, each containing 100 mg of the N-oxide in one tablet (170 mg), are prepared.

Example 22 Capsules

10 A 10% hydroxypropylcellulose solution is added to a mixture consisting of 50 g of 4-benzyloxy-2-(10-carboxydecyl) quinoline-N-oxide, 80 g of lactose and 38 g of potato starch, and the mixture is kneaded. The mixture is granulated in the same manner as in Example 21, and
15 after addition of magnesium stearate, capsules each containing 50 mg of the N-oxide in one capsule (170 mg) are prepared according to an ordinary procedure.

Example 23 Soft Capsules

20 At first, 10 g of 4-hydroxy-2-[11-(2-tetrahydro-pyranyloxy) undecyl] quinoline-N-oxide is dissolved in 100 g of soybean oil, and the solution is filled into capsules, each containing 10 mg of the N-oxide, according to the ordinary procedure, to prepare soft capsules.

25

Example 24 Ointment

At first, 20 g of 4-hydroxy-2-(11,11-dimethoxy-undecyl) quinoline-N-oxide is mixed with a mixture of white vaseline and liquid paraffin to prepare an ointment con-
30 taining 100 mg/g of the N-oxide.

Experimental Example

Inhibiting actions of test compounds shown in Table 2 on lipoxygenase in vitro were determined according to the following procedure.

5 Procedure for determining inhibiting actions on leukocyte 5-lipoxygenase:

 Determination was conducted according to the modified B. A. Jakschik et al procedure [Biochim. Biophys. Res. Commun. 95, 103 (1980)]. That is, Leukemic basophilic
10 granulocyte (RBL-1, ATCC NO. CRL 1378) cells of rats were used as a 5-lipoxygenase enzyme source, and the cells and a test compound were contacted with each other in a 0.07 M tris hydrochloric acid buffer solution in the presence of
15 0.7 m moles of calcium chloride at 37°C for 5 minutes, and then 20 µmoles of [¹⁴C]-arachidonic acid was added thereto. The mixture was subjected to reaction at 37°C for 5
minutes. The reaction product was extracted with ethyl acetate / methanol / 0.2 M citric acid (30 / 4 / 1) and the extract was subjected to a thin layer chromatographic
20 separation (developing solvent: petroleum ether / ethyl ether / acetic acid = 50 / 50 / 1), and the spot of 5-hydroxy-5,8,10,14-eicosatetraenoic acid in the product was scraped off and ¹⁴C was measured by a liquid scintillation counter.

 The result is shown in Table 2, from which it
25 is obvious that the test compounds show an inhibiting action on the 5-lipoxygenase enzyme. The well-known compound BW-755C, i.e. 3-amino-1-(3-trifluoromethylphenyl)-2-pyrazoline hydrochloride is shown for comparison in
Table 2.

30

35

Table 2

5	Compound Ex. No.	5-lipoxygenase- inhibiting concentration *1 IC50 (μ M)	Compound Ex. No.	5-lipoxygenase- inhibiting concentration *1 IC50 (μ M)
	2	2.7 % *2	4	1.6 % *2
	13	11.5 % *2	3	0.28
	1 - (2)	7.7 % *2	14	0.16
10	6	20.0 % *2	20	1.7
	7	33.1 % *2	15	2.7
	8	27.3 % *2	16	0.25
	9	27.0 % *2	17	0.27
	10	32.4 % *2	18	0.46
15	11	36.6 % *2	19	0.18
	12	37.2 % *2	5	0.22
			BW-755C	4.0

20 *1 Concentration of compound required for 50% inhibition of the enzyme activity.

*2 Percent inhibition at 1 μ M compound concentration.


25

30

35

WHAT IS CLAIMED IS:

1. A quinoline-N-oxide derivative represented by the formula:



wherein X is hydroxy, lower alkoxy, lower alkylthio, unsubstituted or substituted aralkyloxy, or unsubstituted or substituted aralkylthio; Y is a hydrogen atom or halogen atom; R₁ is alkylene or alkenylene having 3 to 15 carbon atoms; Z is hydroxymethyl, lower alkoxymethyl, unsubstituted or substituted aryloxymethyl, tetrahydropyranyloxymethyl, tetrahydrofuranyloxymethyl; unsubstituted or substituted arylsulfonyloxymethyl, lower alkylthiomethyl, unsubstituted or substituted arylthiomethyl, lower alkylsulfinylmethyl, unsubstituted or substituted arylsulfinylmethyl, lower alkylsulfonylmethyl, unsubstituted or substituted arylsulfonylmethyl, aminomethyl, -CH₂NHR₂

wherein R₂ is lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl,

-CH₂NR₃R₄

wherein R₃ and R₄ are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl,

-CH₂N⁺R₅R₆R₇

wherein R₅, R₆, and R₇ are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl, where the counterion is an anion of acid or a hydroxyl ion,

-COR₈

wherein R₈ is a hydrogen atom, lower alkyl or hydroxy

-CH(OR₉)₂

5 wherein R₉ is lower alkyl, iminomethyl, hydroxyiminomethyl, or a halogen atom, and its salts.

2. A quinoline-N-oxide derivative and its salts
10 according to claim 1, wherein the substituent appearing in said substituted aralkyloxy, substituted aralkylthio, substituted aralkyl, substituted aryloxymethyl, substituted arylsulfonyloxymethyl, substituted arylthiomethyl, substituted arylsulfinylmethyl, substituted arylsulfonylmethyl
15 and substituted aryl is a substituent on the aryl ring and is selected from the group consisting of lower alkyl, lower alkoxy, halogen atom, nitro and hydroxy.

3. A quinoline-N-oxide derivative and its salts
20 according to claim 1, wherein R₁ is alkylene or alkenylene having 5 to 15 carbon atoms.

4. A quinoline-N-oxide derivative and its salts
according to claim 1, wherein said salts are pharmacologically acceptable base addition salts or pharmacologically
25 acceptable acid addition salts.

5. A pharmaceutical composition, which comprises
a quinoline-N-oxide derivative defined by claim 1 or a
pharmacologically acceptable salt thereof, as an active
30 ingredient, and at least one pharmaceutically acceptable carrier.



European Patent
Office

EUROPEAN SEARCH REPORT

0177764
Application number

EP 85 11 1243

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	CHEMICAL ABSTRACTS, vol. 92, 1980, page 115, no. 191852m, Columbus, Ohio, US; P. RICCIO et al.: "Interaction of 3-(3H)-2-n-nonyl-4-hydroxyquinoline-N-oxide with submitochondrial particles from beef heart. I. Inhibition of respiratory activity", & BOLL. SOC. ITAL. BIOL. SPER. 1979, 55(23), 2506-11 * Abstract *	1,5	C 07 D 215/60 C 07 D 405/12 A 61 K 31/47
P,A	EP-A-0 128 374 (KYOWA HAKKO KOGYO) * Claim 1 *	1,5	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			C 07 D 215/00 C 07 D 405/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 09-12-1985	Examiner ALFARO I.
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			